Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses | ||||
| Cost of product sales | 28,316 | 20,734 | 53,107 | 41,126 |
| Research and development | 81,555 | 77,951 | 158,423 | 156,216 |
| Selling, general and administrative | 160,252 | 133,507 | 331,271 | 259,877 |
| Total operating expenses | 270,123 | 232,192 | 542,801 | 457,219 |
| Income from operations | 37,836 | 32,374 | 33,220 | 51,663 |
| Interest income, net | 7,990 | 7,243 | 16,045 | 15,144 |
| Other income | 647 | 594 | 1,189 | 1,183 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's SG&A?
- Acadia Pharmaceuticals (ACAD) reported SG&A of $160.25M in Q2 2026.
- How has Acadia Pharmaceuticals's SG&A changed year-over-year?
- Acadia Pharmaceuticals's SG&A increased by 20.0% year-over-year, from $133.51M to $160.25M.
- What is the long-term trend for Acadia Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's SG&A has grown at a 8.5% compound annual growth rate (CAGR), from $396.03M to $548.89M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Acadia Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude